Literature DB >> 10209486

Infrequent bax gene mutations in B-cell lymphomas.

H Peng1, A Aiello, G Packham, P G Isaacson, L Pan.   

Abstract

Mutation of the bax gene has been reported previously in lymphoid cell lines. In vitro experiments have shown that alterations in promoter and coding sequences of the gene abolish its apoptosis initiation function, which is considered crucial for tumour development. To assess bax gene mutations in lymphomagenesis, polymerase chain reaction-based single strand conformation polymorphism analysis (PCR-SSCP) and direct sequencing were used to detect altered sequences in the promoter region and all the six exons and their flanking sequences of the gene. Nodal and extranodal B-cell lymphomas (n = 112) including follicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, splenic marginal zone B-cell lymphoma and low- and high-grade mucosa-associated lymphoid tissue (MALT) lymphomas were studied. Sequence alterations were found in 11 cases. Nine also showed the same altered sequences in corresponding non-tumour control tissue samples, indicating polymorphism. In the remaining two cases, sequence alterations (in exons 3 and 6) which altered the bax open reading frame were observed only in tumour tissues, indicating tumour-specific point mutation. These results suggest that inhibition of apoptosis through bax gene mutations is unlikely to be a common event in B-cell lymphoma, at least in the major types of nodal and extranodal B-cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10209486     DOI: 10.1002/(SICI)1096-9896(199812)186:4<378::AID-PATH203>3.0.CO;2-5

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  5 in total

1.  Molecular detection of the G(-248)A BAX promoter nucleotide change in B cell chronic lymphocytic leukaemia.

Authors:  O Moshynska; K Sankaran; A Saxena
Journal:  Mol Pathol       Date:  2003-08

Review 2.  Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia.

Authors:  Graham Packham; Freda K Stevenson
Journal:  Immunology       Date:  2005-04       Impact factor: 7.397

3.  Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.

Authors:  C M Eischen; M F Roussel; S J Korsmeyer; J L Cleveland
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

4.  Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis.

Authors:  Sean P Garrison; John R Jeffers; Chunying Yang; Jonas A Nilsson; Mark A Hall; Jerold E Rehg; Wen Yue; Jian Yu; Lin Zhang; Mihaela Onciu; Jeffery T Sample; John L Cleveland; Gerard P Zambetti
Journal:  Mol Cell Biol       Date:  2008-06-23       Impact factor: 4.272

5.  BAK, BAX, and NBK/BIK proapoptotic gene alterations in Iranian patients with ataxia telangiectasia.

Authors:  Anna Isaian; Natalia V Bogdanova; Masoud Houshmand; Masoud Movahadi; Asghar Aghamohammadi; Asghar Agamohammadi; Nima Rezaei; Lida Atarod; Mahnaz Sadeghi-Shabestari; Seyed Hasan Tonekaboni; Zahra Chavoshzadeh; Seyed Mohammad Seyed Hassani; Reza Mirfakhrai; Taher Cheraghi; Najmoddin Kalantari; Mitra Ataei; Thilo Dork-Bousset; Mohammad Hossein Sanati
Journal:  J Clin Immunol       Date:  2009-11-07       Impact factor: 8.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.